Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Depreciation & Amortization (CF) data on record, last reported at $3.0 million in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 25.0% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $8.0 million, down 27.27%, while the annual FY2023 figure was $15.0 million, N/A changed from the prior year.
  • Depreciation & Amortization (CF) reached $3.0 million in Q3 2025 per INDV's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.0 million in Q1 2024 and bottomed at $2.0 million in Q2 2024.